Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Payables: 2019-2025

Historic Payables for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $9.5 million.

  • Beam Therapeutics' Payables rose 150.39% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year increase of 150.40%. This contributed to the annual value of $3.9 million for FY2024, which is 139.39% up from last year.
  • Per Beam Therapeutics' latest filing, its Payables stood at $9.5 million for Q3 2025, which was down 9.58% from $10.6 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Payables peaked at $14.1 million during Q1 2023, and registered a low of $1.6 million during Q4 2023.
  • Moreover, its 3-year median value for Payables was $4.4 million (2024), whereas its average is $6.2 million.
  • As far as peak fluctuations go, Beam Therapeutics' Payables slumped by 82.09% in 2023, and later skyrocketed by 175.95% in 2025.
  • Over the past 5 years, Beam Therapeutics' Payables (Quarterly) stood at $7.5 million in 2021, then grew by 20.81% to $9.0 million in 2022, then plummeted by 82.09% to $1.6 million in 2023, then skyrocketed by 139.39% to $3.9 million in 2024, then soared by 150.39% to $9.5 million in 2025.
  • Its Payables stands at $9.5 million for Q3 2025, versus $10.6 million for Q2 2025 and $7.7 million for Q1 2025.